Yindan Pinggan Capsules alleviates acetaminophen-induced liver injury by modulating ferroptosis via the system Xc−/GSH/GPX4 axis and the LPCAT3–ACSL4 pathway
Randomized trial evaluates Yindan Pinggan Capsules' effects on liver injury from acetaminophen, suggesting new therapies.
Key Points
This study aimed to assess the protective effects of Yindan Pinggan Capsules against acetaminophen-induced liver injury and explore the underlying mechanisms.
Male mice were administered Yindan Pinggan Capsules daily for 7 days, followed by an acetaminophen injection to induce liver injury.
Histopathological examinations and molecular analyses, including Western blot and proteomics, were performed to evaluate liver injury and signaling pathways.
Gene Expression Omnibus data and network pharmacology were utilized to elucidate the modulation of key signaling pathways.
Yindan Pinggan Capsules reduced serum levels of interleukin-6 and interleukin-1β, indicating decreased inflammation.
The capsules lowered alanine aminotransferase and aspartate aminotransferase levels associated with liver injury.
YDPG was found to modulate the ferroptosis pathway, impacting proteins linked to hepatoprotective effects.